Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board
Feasibility of Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board in Cancer Patients
H. Lee Moffitt Cancer Center and Research Institute
35 participants
May 5, 2020
OBSERVATIONAL
Conditions
Summary
This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.
Eligibility
Inclusion Criteria5
- Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care.
- Participant must have a life expectancy greater than 3 months
- Participant must have an ECOG performance status 0-2
- Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB
- Willingness to be followed over time and allowing collection of clinical data including scans and serial blood sampling.
Exclusion Criteria1
- None
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and results of ETB recommendation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04343365